cancer

Vitamin D enhances the response to cancer immunotherapy in mice via the gut microbiome, according to a study published in Science. The role of vitamin D in cancer immune modulation had already been studied in previous studies. Now, the authors suggest that this nutrient acts on intestinal epithelial cells, altering the composition of the microbiome and favoring a species of bacteria called Bacteroides fragilis, which regulates immunity against cancer.   

Although breast cancer mortality has reduced by more than 40% in most high-income countries, a Lancet commission warns that one million people will die from the disease by 2040, especially in low- and middle-income countries. The authors highlight some of the knowledge gaps that persist about the disease, such as the lack of knowledge about the number of patients living with metastatic breast cancer and their needs, or the costs associated with breast cancer - including physical, psychological, social and economic costs - which, according to the authors, are immense but underestimated, and not adequately reflected in global health indicators. 

A French study involving more than 100,000 women has found a link between long-term use of some progesterone hormone analogues - used for contraception or hormone replacement therapy - and an increased risk of developing meningioma, a generally benign type of brain tumour. The results are published in The BMJ. 

An international team of researchers has examined the epigenetic effects of tobacco and e-cigarettes over time in more than 3,500 samples. Their results indicate that e-cigarettes can also cause changes associated with an increased risk of cancer even shortly after starting to use them. They publish the study in the journal Cancer Research. 

Two studies published in the New England Journal of Medicine evaluate colorectal cancer screening tests that could be alternatives to the existing faecal immunochemical test (FIT), which detects occult blood in stool. The first study uses a new generation test that detects DNA in stool and has a higher sensitivity than FIT, 93.9% for colorectal cancer and 90.6% for advanced neoplasia (tumour formation). The second uses a blood-based DNA detection test with a sensitivity of 83% for colorectal cancer and 90% for advanced neoplasia.   

A treatment using lights and sound pulses can protect mice from cognitive decline associated with chemotherapy, according to a research team at the Massachusetts Institute of Technology in the US. The benefits are greatest when the therapy is used early and preventively at the same time as chemotherapy, says the study, published in Science Translational Medicine. The use of this non-invasive sensory stimulation therapy to alleviate other pathologies has already been studied.

US research has analysed data from more than 300,000 people and found that both men with fertility problems and their family members have an increased risk of developing various types of cancer and at an earlier age. The results are published in the journal Human Reproduction.

A multidisciplinary study involving several Spanish research groups has preclinically tested a new type of immunotherapy for multiple myeloma. Instead of modifying T cells to attack the tumour directly, as CAR-T cells do, they have managed to make them secrete bispecific antibodies, which bind to the tumour on one side and to other T cells on the other, attracting them to the tumour. According to the authors, this cell therapy was more effective than traditional CAR-Ts and could generate less resistance. The results are published in the journal Science Translational Medicine. 

By 2050, there will be more than 35 million new cases of cancer worldwide, an increase of 77% from the 20 million cases reported in 2022. These are projections made by the WHO's International Agency for Research on Cancer (IARC), which has published the latest estimates of the global burden of cancer. Using data from 185 countries, IARC estimates that in 2022 lung cancer was the most common cancer worldwide, with female breast cancer in second place, followed by colorectal, prostate and stomach cancer. The authors stress the urgent need to address inequalities around these diseases.

International research estimates that by 2024 there will be approximately 1,270,800 deaths from different types of cancer in the European Union (EU) as a whole. In the specific case of colorectal cancer, the researchers estimate that mortality rates will increase among people aged between 25 and 49 in the EU. In Spain, the increase will be 5.5 % in men. The authors of the research, published in the Annals of Oncology, attribute this increased mortality to overweight, obesity and alcohol consumption in this age group.